2021 ASCRS Annual Meeting Announcement
Register Now for the 2021 ASCRS and ASOA Annual Meetings!
Don’t miss your chance to learn directly from the world’s top thought leaders and researchers in ophthalmology, hear from inspiring speakers, and meet with colleagues face to face.
Price increase notice!
The cost to attend the 2021 ASCRS and ASOA Annual Meetings increases on June 24. Now is the time to register, book housing, and begin planning for this unique experience.
In an effort to reduce high prescription drug costs, the Trump administration announced in 2018 a new policy that was effective January 1, 2019, to permit Medicare Advantage (MA) Plans to begin using step therapy for Part B drugs administered in the office or facility. Following the policy announcement, CMS released a final rule, opposed by ASCRS and the medical community, which codifies the use of step therapy in MA plans and expands step therapy and prior authorization in Part D plans effective on January 1, 2020.Issue Brief
How it Impacts You
Step therapy, also known as “fail first,” is a cost-containment strategy that requires physicians to prescribe an insurer’s preferred treatment first, and only covers more expensive treatments if the patient does not respond to the initial treatment. Previously, MA plans were prohibited from using step therapy; however, as part of the overall effort to reduce the costs of prescription drugs, CMS announced in August 2018 that plans may begin using step therapy for the 2019 benefit year.